This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Goldfarb Branham Law Firm LLP Investigating Potentially Unfair Buyout Of Abraxis

Goldfarb Branham LLP is investigating shareholder claims due to the buyout of Abraxis Bioscience (NASDAQ: ABII) to Celgene (NASDAQ: CELG). The national securities litigation firm is examining the potential unfairness of the price and process. Shareholders with information or concerns are urged to contact attorney Hamilton Lindley at 877-583-2855 or hlindley@goldfarbbranham.com.

“Abraxane, a breast cancer treatment drug produced by the company, experienced a 25% increase in revenue in the first quarter alone,” says shareholder attorney Hamilton Lindley. “If this buyout is approved, Celenge will experience this growth, while Abraxis shareholders will be paid $58 in cash plus 0.2617 shares for each share of Abraxis they own.”

Goldfarb Branham LLP lawyers have significant success representing investors involved in unfair buyouts nationwide. The firm’s lawyers have been counsel on over 100 securities cases and provide nimble, creative and effective counsel at all stages of complex litigation. For more information on the buyout and your rights, you are encouraged to contact Hamilton Lindley at 877-583-2855 or hlindley@goldfarbbranham.com.



Copyright Business Wire 2010

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG
AAPL $124.75 0.00%
FB $80.78 0.00%
GOOG $524.05 0.00%
TSLA $206.79 0.00%
YHOO $44.45 0.00%

Markets

DOW 17,826.30 -279.47 -1.54%
S&P 500 2,081.18 -23.81 -1.13%
NASDAQ 4,931.8150 -75.9760 -1.52%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs